Thursday, July 31, 2008
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic M
Clinical Program Leverages Quark's RNAi Technology FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics,...
Sunday, July 20, 2008
Dr. Mark Behlke, Dr John Rossi and team have been gaining deeper understanding of the Mechanism of Dicer-substrate small-interfering RNA (DsiRNA) processing. This understanding is leading to better and better designs of the RNA duplexes. These designs or chemical modifications are necessary steps in the drug design and development process.
This publication looks at design from the perspective of:
I believe this is an important publication for researchers wanting to better understand:
The mechanisms behind successful delivery of DsiRNA for gene expression studies.
Variations in potency.
upload article: oligo-18-p187-2008-collingwood-dsirna-modifications1
Tuesday, July 8, 2008
Target Discovery and Validation
in vivo RNAi-recent in vivo RNAi Pubs
Bioinformatics of small RNAs
siRNA library screens